{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:34Z","timestamp":1793361814415,"version":"4.5.0"},"reference-count":119,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) comprises a heterogeneous group of inflammatory and fibrotic conditions, often resulting in progressive lung function decline and increased mortality. Connective tissue disease (CTD) should be considered in all patients with ILD, as distinguishing between CTD-ILD and other forms of fibrotic lung disease has important therapeutic and prognostic implications. The idiopathic inflammatory myopathies (IIM) represent a CTD subtype of growing interest to ILD experts. The expansion and availability of myositis-specific and myositis-associated antibody testing has allowed for improved disease detection and characterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>In this review, we highlight the relationship between myositis antibodies and ILD. Select forms of IIM, such as the antisynthetase syndrome and clinically amyopathic dermatomyositis can present with rapidly progressive ILD, warranting timely disease diagnosis and management. Disease phenotypes, prevalence, laboratory testing, prognosis, and management strategies are described according to select myositis antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Myositis antibodies provide valuable information for clinicians managing patients with ILD. This review aims to increase awareness of their role in disease detection, pathophysiology, and possibly therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfab108","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T07:39:02Z","timestamp":1631086742000},"page":"240-258","source":"Crossref","is-referenced-by-count":28,"title":["Myositis Antibodies and Interstitial Lung Disease"],"prefix":"10.1093","volume":"7","author":[{"given":"Manpreet","family":"Basuita","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M","family":"Fidler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Department of Medicine, Division of Respirology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"},{"name":"Department of Medicine, Division of Respirology, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"2022010916494198500_jfab108-B1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2022010916494198500_jfab108-B2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2022010916494198500_jfab108-B3","first-page":"1","article-title":"New Myositis Classification Criteria\u2014What We Have Learned Since Bohan and Peter","volume":"20","author":"Leclair","year":"2018","journal-title":"Current Rhematology Reports"},{"key":"2022010916494198500_jfab108-B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"2022010916494198500_jfab108-B5","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur Respir Rev"},{"key":"2022010916494198500_jfab108-B7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J Immunol Methods"},{"key":"2022010916494198500_jfab108-B9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B10","first-page":"17","article-title":"SRP-mediated protein targeting: structure and function revisited","volume":"1694","author":"Luirink","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"2022010916494198500_jfab108-B11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2022010916494198500_jfab108-B12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"ATS\/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2022010916494198500_jfab108-B13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022010916494198500_jfab108-B14","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916494198500_jfab108-B15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-Ku antibodies: clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2022010916494198500_jfab108-B18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"2022010916494198500_jfab108-B19","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s10067-019-04729-5","article-title":"Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum","volume":"38","author":"Yamaguchi","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2022010916494198500_jfab108-B20","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"2022010916494198500_jfab108-B21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"2022010916494198500_jfab108-B22","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.1956.02960520029008b","article-title":"Interstitial pneumonitis in dermatomyositis","volume":"160","author":"Mills","year":"1956","journal-title":"J Am Med Assoc"},{"key":"2022010916494198500_jfab108-B24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1378\/chest.65.4.403","article-title":"Interstitial pneumonitis in association with polymyositis and dermatomyositis","volume":"65","author":"Frazier","year":"1974","journal-title":"Chest"},{"key":"2022010916494198500_jfab108-B25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2022010916494198500_jfab108-B27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","article-title":"Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study","volume":"4","author":"Ikeda","year":"2015","journal-title":"Springerplus"},{"key":"2022010916494198500_jfab108-B28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"2022010916494198500_jfab108-B29","doi-asserted-by":"crossref","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS One"},{"key":"2022010916494198500_jfab108-B30","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3899\/jrheum.101002","article-title":"Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan","volume":"38","author":"Yamasaki","year":"2011","journal-title":"J Rheumatol"},{"key":"2022010916494198500_jfab108-B31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"2022010916494198500_jfab108-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022010916494198500_jfab108-B33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3899\/jrheum.160618","article-title":"A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for Antisynthetase syndrome","volume":"44","author":"Aggarwal","year":"2017","journal-title":"J Rheumatol"},{"key":"2022010916494198500_jfab108-B34","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00415-019-09266-4","article-title":"Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study","volume":"266","author":"Montagnese","year":"2019","journal-title":"J Neurol"},{"key":"2022010916494198500_jfab108-B35","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916494198500_jfab108-B36","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916494198500_jfab108-B37","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B38","doi-asserted-by":"publisher","first-page":"e85062","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PLoS One"},{"key":"2022010916494198500_jfab108-B39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2022010916494198500_jfab108-B40","doi-asserted-by":"crossref","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"2022010916494198500_jfab108-B41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"2022010916494198500_jfab108-B43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/rheumatology\/key451","article-title":"Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis","volume":"58","author":"Infantino","year":"2019","journal-title":"Rheumatology (Oxford"},{"key":"2022010916494198500_jfab108-B44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"2022010916494198500_jfab108-B45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022010916494198500_jfab108-B46","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"key":"2022010916494198500_jfab108-B47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2022010916494198500_jfab108-B48","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"2022010916494198500_jfab108-B49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","article-title":"Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2022010916494198500_jfab108-B50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B51","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022010916494198500_jfab108-B52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Anti-melanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"2022010916494198500_jfab108-B53","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022010916494198500_jfab108-B54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/ard.46.1.23","article-title":"Pulmonary disease in polymyositis\/dermatomyositis: a clinicopathological analysis of 65 autopsy cases","volume":"46","author":"Lakhanpal","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B55","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-020-05291-1","article-title":"Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"40","author":"Li","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2022010916494198500_jfab108-B57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity"},{"key":"2022010916494198500_jfab108-B58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"2022010916494198500_jfab108-B59","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B60","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","article-title":"Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis","volume":"59","author":"Zuo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916494198500_jfab108-B61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin Immunol Immunopathol"},{"key":"2022010916494198500_jfab108-B62","article-title":"Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis","author":"Liang","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2022010916494198500_jfab108-B63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"key":"2022010916494198500_jfab108-B64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B65","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022010916494198500_jfab108-B67","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2169\/internalmedicine.0662-17","article-title":"Interstitial lung disease is a possible manifestation of anti-signal recognition particle antibody syndrome","volume":"57","author":"Tanino","year":"2018","journal-title":"Intern Med"},{"key":"2022010916494198500_jfab108-B68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022010916494198500_jfab108-B69","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2022010916494198500_jfab108-B70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2019-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"2022010916494198500_jfab108-B71","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/cells10051146","article-title":"Anti-cN1A antibodies are associated with more sever dysphagia in sporadic inclusion body myositis","volume":"10","author":"Lucchini","year":"2021","journal-title":"Cells"},{"key":"2022010916494198500_jfab108-B72","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B73","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/mus.27157","article-title":"Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis","volume":"63","author":"Paul","year":"2021","journal-title":"Muscle Nerve"},{"key":"2022010916494198500_jfab108-B74","doi-asserted-by":"crossref","first-page":"e854","DOI":"10.1016\/j.amjmed.2019.06.023","article-title":"Development of autoimmune interstitial lung disease in a patient with inclusion body myositis","volume":"132","author":"He","year":"2019","journal-title":"Am J Med"},{"key":"2022010916494198500_jfab108-B75","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"2022010916494198500_jfab108-B76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody","volume":"44","author":"Guillen-Del Castillo","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B77","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study","volume":"10","author":"Ghillani","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2022010916494198500_jfab108-B78","doi-asserted-by":"crossref","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"key":"2022010916494198500_jfab108-B79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","article-title":"Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study","volume":"57","author":"Reiseter","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916494198500_jfab108-B80","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2022010916494198500_jfab108-B81","doi-asserted-by":"crossref","first-page":"i134","DOI":"10.1093\/rheumatology\/keu114.001","article-title":"Isolated anti-Ro52 antibodies: clinical significance in routine practice","volume":"53","author":"Malik","year":"2014","journal-title":"Rheumatology"},{"key":"2022010916494198500_jfab108-B82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine (Baltimore"},{"key":"2022010916494198500_jfab108-B83","doi-asserted-by":"crossref","first-page":"e4713","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2022010916494198500_jfab108-B84","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2022010916494198500_jfab108-B85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00408-019-00212-9","article-title":"Screening for myositis antibodies in idiopathic interstitial lung disease","volume":"197","author":"Fidler","year":"2019","journal-title":"Lung"},{"key":"2022010916494198500_jfab108-B86","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.rmed.2011.03.022","article-title":"Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias","volume":"105","author":"Watanabe","year":"2011","journal-title":"Respir Med"},{"key":"2022010916494198500_jfab108-B87","doi-asserted-by":"crossref","first-page":"1759720X20975907","DOI":"10.1177\/1759720X20975907","article-title":"The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study","volume":"12","author":"Lackner","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022010916494198500_jfab108-B88","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"2022010916494198500_jfab108-B89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rmed.2017.03.028","article-title":"Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies","volume":"132","author":"Scir\u00e8","year":"2017","journal-title":"Respir Med"},{"key":"2022010916494198500_jfab108-B90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3899\/jrheum.171314","article-title":"Rheumatological assessment is important for interstitial lung disease diagnosis","volume":"45","author":"Levi","year":"2018","journal-title":"J Rheumatol"},{"key":"2022010916494198500_jfab108-B91","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrrheum.2011.39","article-title":"Pathogenesis, classification and treatment of inflammatory myopathies","volume":"7","author":"Zong","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2022010916494198500_jfab108-B92","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun"},{"key":"2022010916494198500_jfab108-B93","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar1862","article-title":"In adult onset myositis, the presence of interstitial lung disease and myositis specific\/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype","volume":"8","author":"Chinoy","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2022010916494198500_jfab108-B94","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","article-title":"Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study","volume":"71","author":"Chinoy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","article-title":"Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation","volume":"29","author":"Katsumata","year":"2007","journal-title":"J Autoimmun"},{"key":"2022010916494198500_jfab108-B96","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/art.24683","article-title":"Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells","volume":"60","author":"Barbasso Helmers","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B97","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: association of HLA-DRB10101\/0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B98","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/MCP.0000000000000698","article-title":"Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases","volume":"26","author":"Yanagihara","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"2022010916494198500_jfab108-B99","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.190.6.815","article-title":"Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity","volume":"190","author":"Casciola-Rosen","year":"1999","journal-title":"J Exp Med"},{"key":"2022010916494198500_jfab108-B100","doi-asserted-by":"publisher","first-page":"567184","DOI":"10.3389\/fpubh.2020.567184","article-title":"Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit?","volume":"8","author":"Audi","year":"2020","journal-title":"Front Public Health"},{"key":"2022010916494198500_jfab108-B101","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/art.1780341108","article-title":"Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies","volume":"34","author":"Leff","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B102","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/art.21198","article-title":"Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups","volume":"52","author":"Sarkar","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022010916494198500_jfab108-B103","doi-asserted-by":"crossref","first-page":"e001202","DOI":"10.1136\/rmdopen-2020-001202","article-title":"Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease","volume":"6","author":"Nishina","year":"2020","journal-title":"RMD Open"},{"key":"2022010916494198500_jfab108-B104","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa066157","article-title":"Telomerase mutations in families with idiopathic pulmonary fibrosis","volume":"356","author":"Armanios","year":"2007","journal-title":"N Engl J Med"},{"key":"2022010916494198500_jfab108-B105","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/annrheumdis-2020-218918","article-title":"Autoantibodies targeting telomere-associated proteins in systemic sclerosis","volume":"80","author":"Adler","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022010916494198500_jfab108-B106","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022010916494198500_jfab108-B107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"key":"2022010916494198500_jfab108-B108","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"2022010916494198500_jfab108-B109","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2022010916494198500_jfab108-B110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"2022010916494198500_jfab108-B111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"2022010916494198500_jfab108-B112","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"key":"2022010916494198500_jfab108-B113","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"2022010916494198500_jfab108-B114","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022010916494198500_jfab108-B115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab Versus Cyclophosphamide for the Treatment of Connective Tissue Disease-associated Interstitial Lung Disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"2022010916494198500_jfab108-B116","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.lpm.2019.03.017","article-title":"Plasma exchange in anti-glomerular basement membrane disease","volume":"48","author":"Prendecki","year":"2019","journal-title":"Presse Med"},{"key":"2022010916494198500_jfab108-B117","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"2022010916494198500_jfab108-B118","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jca.21387","article-title":"Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease","volume":"30","author":"Omotoso","year":"2015","journal-title":"J Clin Apher"},{"key":"2022010916494198500_jfab108-B119","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/240\/42084131\/jfab108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/240\/42084131\/jfab108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T11:51:49Z","timestamp":1641729109000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/7\/1\/240\/6498265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,5]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfab108","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]}}}